Red Light Therapy Shows Promise for Treating Brain Injuries

Why It Matters

If validated, PBM offers a non‑invasive, proactive tool to reduce cumulative brain injury risk in contact sports, potentially reshaping concussion management and athlete health protocols.

Key Takeaways

• RHAEs cause subclinical brain changes in football players
• PBM uses near‑infrared light to boost mitochondrial function
• Study: 26 NCAA athletes, 16‑week, active vs sham
• Active PBM stabilized diffusion MRI biomarkers versus sham
• Findings suggest red‑light may protect against impact‑induced damage

Pulse Analysis

Repetitive head acceleration events (RHAEs) have emerged as a silent epidemic in contact sports, generating micro‑structural brain alterations even when athletes do not sustain a diagnosed concussion. Advanced imaging studies reveal that these subclinical impacts can erode white‑matter integrity, elevate neuroinflammatory markers, and subtly impair cognitive function over a season. Traditional management relies on post‑injury rest and symptom monitoring, leaving a therapeutic gap for preventing the cumulative cellular damage that underlies long‑term neurological risk. As leagues confront mounting liability and player‑health concerns, the search for proactive, non‑invasive interventions has intensified.

Photobiomodulation, commonly known as red‑light therapy, delivers near‑infrared photons to mitochondria, prompting cytochrome c oxidase to increase ATP production and improve cerebral blood flow. This metabolic boost enhances neuronal resilience, allowing cells to better tolerate oxidative stress and mechanical strain. Prior animal models and small human trials have demonstrated reduced inflammation and accelerated recovery after traumatic brain injury when PBM is applied within hours of impact. The modality’s non‑pharmacologic nature, ease of self‑administration, and minimal side‑effect profile make it an attractive candidate for routine use among athletes.

In a recent University of Utah Health trial, 26 Division I football players were randomized to active or sham transcranial and intranasal PBM for 16 weeks, receiving three weekly sessions. Diffusion MRI at season’s end showed the sham group with increased restricted diffusion and quantitative anisotropy—signatures of neuroinflammation—while the active group maintained stable biomarker levels, suggesting protective effects. Although the sample size was modest and lacked a non‑contact control, the findings align with a growing body of evidence that red‑light therapy can mitigate impact‑related neural stress. Larger, multi‑sport studies could solidify PBM’s role in concussion‑prevention protocols and reshape athlete health management.